Marlio Charles Mosseri Purchases 50,000 Shares of Nuvectis Pharma (NASDAQ:NVCT) Stock

Nuvectis Pharma, Inc. (NASDAQ:NVCT) major shareholder Marlio Charles Mosseri purchased 50,000 shares of the stock in a transaction on Tuesday, June 30th. The shares were purchased at an average cost of $18.32 per share, with a total value of $916,000.00. Following the transaction, the insider owned 3,186,576 shares of the company’s stock, valued at $58,378,072.32. This trade represents a 1.59% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Nuvectis Pharma Price Performance

Shares of NASDAQ:NVCT opened at $19.57 on Friday. The business has a 50-day moving average of $12.50 and a two-hundred day moving average of $9.83. The firm has a market capitalization of $519.19 million, a PE ratio of -14.94 and a beta of -0.24. Nuvectis Pharma, Inc. has a 12 month low of $5.55 and a 12 month high of $29.27.

Nuvectis Pharma (NASDAQ:NVCT) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.04. As a group, research analysts anticipate that Nuvectis Pharma, Inc. will post -1.01 earnings per share for the current year.

Institutional Investors Weigh In On Nuvectis Pharma

Several hedge funds have recently modified their holdings of the stock. Iridian Asset Management LLC CT lifted its position in Nuvectis Pharma by 44.5% during the 4th quarter. Iridian Asset Management LLC CT now owns 586,320 shares of the company’s stock worth $4,427,000 after acquiring an additional 180,699 shares in the last quarter. Occam Crest Management LP grew its position in Nuvectis Pharma by 31.0% in the fourth quarter. Occam Crest Management LP now owns 380,000 shares of the company’s stock valued at $2,869,000 after acquiring an additional 90,000 shares in the last quarter. Oppenheimer & Co. Inc. grew its position in Nuvectis Pharma by 6.5% in the fourth quarter. Oppenheimer & Co. Inc. now owns 73,566 shares of the company’s stock valued at $555,000 after acquiring an additional 4,500 shares in the last quarter. Baldwin Wealth Partners LLC MA raised its stake in shares of Nuvectis Pharma by 11.2% during the fourth quarter. Baldwin Wealth Partners LLC MA now owns 389,625 shares of the company’s stock valued at $2,942,000 after purchasing an additional 39,164 shares during the period. Finally, Geode Capital Management LLC raised its stake in shares of Nuvectis Pharma by 110.8% during the second quarter. Geode Capital Management LLC now owns 285,332 shares of the company’s stock valued at $2,132,000 after purchasing an additional 149,999 shares during the period. 96.77% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nuvectis Pharma in a research note on Friday, June 5th. HC Wainwright raised their target price on shares of Nuvectis Pharma from $13.00 to $39.00 and gave the company a “buy” rating in a research note on Monday, June 22nd. Finally, Wall Street Zen upgraded shares of Nuvectis Pharma from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Nuvectis Pharma currently has an average rating of “Hold” and a consensus target price of $39.00.

Nuvectis Pharma Company Profile

Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake.

The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders.